PDF(Pubmed)
Abstract：
The nectin family comprises four proteins, nectin-1 to -4, which act as cell adhesion molecules. Nectins have various regulatory functions in the immune system and can be upregulated or decreased in different tumors. The literature research was conducted manually by the authors using the PubMed database by searching articles published before 2023 with the combination of several nectin-related keywords. A total of 43 studies were included in the main section of the review. Nectins-1-3 have different expressions in tumors. Both the loss of expression and overexpression could be negative prognostic factors. Nectin-4 is the best characterized and the most consistently overexpressed in various tumors, which generally correlates with a worse prognosis. New treatments based on targeting nectin-4 are currently being developed. Enfortumab vedotin is a potent antibody-drug conjugate approved for use in therapy against urothelial carcinoma. Few reports focus on hepatocellular carcinoma, which leaves room for further studies comparing the utility of nectins with commonly used markers.
摘要：
nectin家族包含四种蛋白质，nectin-1至-4，充当细胞粘附分子。凝集素在免疫系统中具有各种调节功能,并且可以在不同肿瘤中上调或降低。文献研究是由作者使用PubMed数据库手动进行的，方法是搜索2023年之前发表的文章，并结合了几个与nectin相关的关键词。共有43项研究被纳入本综述的主要部分。Nectin-1-3在肿瘤中有不同的表达。表达缺失和过表达都可能是负面的预后因素。Nectin-4是最好的特征和最一致的过度表达在各种肿瘤，这通常与较差的预后相关。目前正在开发基于靶向nectin-4的新疗法。Enfortumabvedotin是一种有效的抗体-药物偶联物，被批准用于治疗尿路上皮癌。很少有报道关注肝细胞癌，这为将nectin的效用与常用标记进行比较的进一步研究留下了空间。
